Additional Context: This information was included in the “The impact of 2025 funding cuts on TB services” annex of the World Health Organization's, or WHO, 2025 Global Tuberculosis Report. 
In 2024, USAID accounted for 9.7% of Indonesia’s tuberculosis funding and the Global Fund for a further 41%. Domestic funding accounted for 47%.

Devex Researcher Note: At the time of the Global Fund's eighth replenishment summit, to which the U.S. committed $4.6 billion — down from its $6 billion pledge in the seventh cycle — it had disbursed only $3.12 billion of that prior commitment, forcing mid-cycle grant cuts of 10% or more across the majority of recipient countries. The exact magnitude of effects on Indonesia are not immediately clear. This measure likely aims to prevent treatment interruptions, one of the main drivers of drug resistance in TB patients, resulting from abrupt funding losses, by reducing Indonesia's dependence on bilateral international funding in favor of more stable multilateral sources, like the Global Fund. Drug-resistant tuberculosis is considered a “persistent threat” in the global fight against tuberculosis, since it is “difficult to diagnose and does not respond to first-line treatment”.

Source: WHO